Wednesday, July 8, 2026

Intelligence · Clinical Development

Pipeline search results

Programs matching “sarilumab” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.

Matching programs 15
Total indexed 20,548
Sponsors 1,769

Quick answer

Showing 15 pipeline programs matching "sarilumab" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.

Refine search

15 results for “sarilumab” Back to intelligence hub

Search results

  1. Sarilumab

    Regeneron UK Limited

    COVID-19

    phase 3 small molecule completed

    1 trial
  2. Sarilumab

    Regeneron UK Limited

    RA

    phase 3 small molecule completed

    1 trial
  3. Sarilumab

    Sanofi Pasteur

    Rheumatoid Arthritis

    phase 3 small molecule terminated

    1 trial
  4. Sarilumab SAR153191

    Regeneron UK Limited

    Giant Cell Arteritis

    phase 3 small molecule terminated

    1 trial
  5. Sarilumab SAR153191

    Regeneron UK Limited

    Corona Virus Infection

    phase 3 small molecule completed

    1 trial
  6. Sarilumab SAR153191 (REGN88)

    Regeneron UK Limited

    Polymyalgia Rheumatica

    phase 3 small molecule terminated

    1 trial
  7. sarilumab SAR153191 (REGN88)

    Regeneron UK Limited

    Rheumatoid Arthritis

    phase 3 small molecule completed

    6 trials
  8. Sarilumab

    Regeneron UK Limited

    Juvenile Idiopathic Arthritis

    phase 2 small molecule completed

    1 trial
  9. Sarilumab

    Regeneron UK Limited

    Ankylosing Spondylitis

    phase 2 small molecule terminated

    2 trials
  10. Sarilumab

    Regeneron UK Limited

    Morphea, Plaque Form

    phase 2 small molecule terminated

    1 trial
  11. Sarilumab SAR153191 (REGN88)

    Regeneron UK Limited

    Juvenile Idiopathic Arthritis

    phase 2 small molecule active

    1 trial
  12. sarilumab

    Sanofi-aventis Healthcare Pty Ltd

    Systemic Juvenile Idiopathic Arthritis (sJIA)

    phase 2 small molecule active

    1 trial
  13. sarilumab SAR153191 (REGN88)

    Sanofi Pasteur

    Rheumatoid Arthritis

    phase 1 small molecule completed

    1 trial
  14. Sarilumab

    Regeneron UK Limited

    Rheumatoid Arthritis

    approved small molecule terminated

    8 trials
  15. Sarilumab

    Regeneron UK Limited

    Polymyalgia Rheumatica

    approved small molecule active

    1 trial

Frequently asked questions

What is the Clinical Development Intelligence Platform?

It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.

How does this compare to Evaluate Pharma or Citeline?

Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.

Where does pipeline data come from?

Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.

Can I follow a company or program for updates?

Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.